SG Americas Securities LLC Has $175,000 Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)

SG Americas Securities LLC reduced its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO) by 60.9% during the 4th quarter, HoldingsChannel reports. The fund owned 7,488 shares of the company’s stock after selling 11,646 shares during the quarter. SG Americas Securities LLC’s holdings in Akero Therapeutics were worth $175,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in AKRO. FMR LLC lifted its position in Akero Therapeutics by 5,491.5% in the 1st quarter. FMR LLC now owns 1,141,285 shares of the company’s stock valued at $43,666,000 after acquiring an additional 1,120,874 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in Akero Therapeutics by 221.2% in the 3rd quarter. Price T Rowe Associates Inc. MD now owns 1,462,424 shares of the company’s stock valued at $49,797,000 after acquiring an additional 1,007,122 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in Akero Therapeutics by 70.6% in the 2nd quarter. Goldman Sachs Group Inc. now owns 1,863,604 shares of the company’s stock valued at $17,612,000 after acquiring an additional 770,924 shares in the last quarter. BlackRock Inc. lifted its position in Akero Therapeutics by 19.3% in the 2nd quarter. BlackRock Inc. now owns 3,321,153 shares of the company’s stock valued at $155,065,000 after acquiring an additional 537,776 shares in the last quarter. Finally, Lord Abbett & CO. LLC lifted its position in Akero Therapeutics by 154.4% in the 3rd quarter. Lord Abbett & CO. LLC now owns 779,126 shares of the company’s stock valued at $39,409,000 after acquiring an additional 472,898 shares in the last quarter.

Insider Activity

In other news, CEO Andrew Cheng sold 75,000 shares of the company’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $32.87, for a total value of $2,465,250.00. Following the sale, the chief executive officer now directly owns 591,416 shares of the company’s stock, valued at approximately $19,439,843.92. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, COO Jonathan Young sold 5,000 shares of the company’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $24.38, for a total value of $121,900.00. Following the transaction, the chief operating officer now owns 263,306 shares in the company, valued at approximately $6,419,400.28. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Andrew Cheng sold 75,000 shares of the company’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $32.87, for a total transaction of $2,465,250.00. Following the completion of the transaction, the chief executive officer now owns 591,416 shares in the company, valued at approximately $19,439,843.92. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 100,646 shares of company stock valued at $3,319,877. 9.69% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research firms recently commented on AKRO. HC Wainwright boosted their price objective on shares of Akero Therapeutics from $40.00 to $43.00 and gave the company a “buy” rating in a research report on Friday, March 1st. UBS Group boosted their price target on shares of Akero Therapeutics from $39.00 to $42.00 and gave the stock a “buy” rating in a research report on Tuesday, March 5th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Akero Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $39.00.

Akero Therapeutics Stock Up 1.6 %

Shares of AKRO stock opened at $22.18 on Monday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 29.27 and a current ratio of 29.27. The firm’s 50-day moving average is $24.53 and its 200-day moving average is $22.30. The stock has a market cap of $1.25 billion, a price-to-earnings ratio of -7.78 and a beta of -0.38. Akero Therapeutics, Inc. has a 52-week low of $11.25 and a 52-week high of $58.38.

Akero Therapeutics (NASDAQ:AKRO) last issued its earnings results on Thursday, February 29th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.17). Sell-side analysts predict that Akero Therapeutics, Inc. will post -4.06 EPS for the current year.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.